Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Emmessar Biotech & Nutrition Ltd has informed the Bombay Stock Exchange that its Audited Financial Results for the quarter ended December 31, 2025 (Q3 FY26) were published in the Free Press Journal and Nav Shakti newspapers on February 12, 2026. This is a routine compliance filing under Regulation 30 (read with Regulation 47) of SEBI's Listing Obligations and Disclosure Requirements, 2015. The letter was signed by Whole Time Director Jeyavel B. Nadar. The actual financial numbers for Emmessar are not included in this filing — only the cover letter confirming the newspaper publication; detailed figures would have been filed separately with the stock exchanges.
No new financial information is disclosed in this filing — it is purely a procedural confirmation that previously filed Q3 FY26 results were published in newspapers as required by SEBI. Shareholders should refer to the earlier detailed results filing on BSE/NSE for actual numbers. Neutral impact on the stock.